Bivalirudin and other hirudin analogs for preserving cellular functionality in clinical cell therapy

摘要

The present invention relates to pharmaceutical compositions for cell therapy with non-embryonic stem cells suitable for stem cell therapy and as the only anticoagulant component at least one thrombin inhibitor which does not interfere with the SDF-1 / CXCR4 signaling pathway. The clinically approved bivalirudin or other hirudin analogs are preferred. The present invention further relates to the corresponding use of these thrombin inhibitors, in particular in the context of cell therapy for cardiovascular diseases.